Nanocrine

Executive Summary

Nanocrine is a private biotechnology company based in Cambridge, MA, pioneering a novel cell secretion imaging platform. Its proprietary technology enables live, label-free, quantitative detection of protein secretions from individual cells with spatial and temporal resolution, functioning as a real-time, microscope-based ELISA. This platform addresses a critical need in drug delivery and biologics by allowing researchers to study cell-to-cell communication in complex biological environments without disrupting the cells, providing unprecedented insights into paracrine signaling, immune modulation, and therapeutic efficacy. Founded in 2016, the company targets applications in immunotherapy development, cell therapy characterization, and biomarker discovery, where understanding the secretory profile of individual cells is paramount. Despite the early stage, Nanocrine's approach has the potential to accelerate drug development by enabling more accurate functional assays and reducing reliance on bulk measurements. The company operates in the competitive landscape of single-cell analysis tools but differentiates through its label-free, real-time capability, which could be a key advantage in both research and eventually clinical applications.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round60% success
• Q3 2026Partnership with Major Pharma for Immuno-Oncology Applications40% success
• TBDPublication of Peer-Reviewed Validation Data in High-Impact Journal70% success